| Prev Close | 303.97 |
| Day Low/High | 300.85 / 308.37 |
| 52 Wk Low/High | 187.72 / 309.66 |
| Avg Volume | 6.06M |
UnitedHealth Group Inc. (UNH)
304.85
NYSE : Health Services
| Exchange | NYSE |
| Shares Outstanding | 948.38M |
| Market Cap | 288.28B |
| EPS | 14.60 |
| P/E Ratio | 21.27 |
| Div & Yield | 4.32 (1.42%) |
Latest News
The Charts of UnitedHealth Group Remain Bullish, Buy a Dip to the $271 Area
Overall the charts and indicators of UNH are constructive.
UnitedHealth Group Gets a Shot in the Arm
UNH has built up a head of steam for an upside breakout.
I Think UnitedHealth Shares Could Return to the February Highs
In this era of economic turbulence created by a public health crisis, this large health insurance company actually affirmed full year guidance for both earnings and net income.
Divining Earnings, Stunning Rebound, Trading Amazon
Are the markets ready for a pause in this dramatic rebound? We are several weeks behind Europe in battling this pandemic and U.S. numbers are far worse. Time will tell.
6 'Work-At-Home' and Telemedicine Stocks You Should Know About
These names should do well as long as the coronavirus is a threat, and still continue to grow once it is past.
UnitedHealth Group Is Leading the Way on the Upside
UNH has moved up strongly from its March nadir so traders and investors should approach from the long side.
UnitedHealth Due for a Checkup
UNH might need to rally above $294 to get the upside going again.
Jim Cramer: One Thing This Market Doesn't Lack Is Confidence
You can sell any stock that's up and take that money to the bank and no one will say, "sorry that was made off of euphoria, we can't take it."
Jim Cramer: In the U.S./China Deal, the Engagement Camp Won
I have been among the most wary of China and its ability to change. I remain that way. But the U.S. got more than I ever thought.
U.S./China Phase One, Yield Curve, Jobs Survey, Trading Disney: Market Recon
One concern for traders and investors would be that the good cheer created by the development of this Phase One deal, as well as actions taken by the FOMC, are nearing or at the point where the headline risk points in the other direction.
Target Provides an Excuse for Selling but Underlying Support Remains Very Strong
Earnings reports are solid but this overbought market is looking for a good reason to consolidate a big move.
Jim Cramer: Why the Tech Stocks Are Back in Favor
The big tech names are once again surging, and as long as they keep their noses clean, that should continue.
My Pick for 2020? You Won't Believe It's Been on Your Screen All Along
This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.
UNH Passes Checkup, but Not With Flying Colors
Despite fluff and puff of UNH's analysts' day, little here screams for getting in right now.
3 Thoughts About UnitedHealth and My Trade Idea
There is no doubt in my mind that the firm is executing at a high level.
UnitedHealth Group Can Pull Back in the Short Run So Look to Buy the Dip
Time to review the charts and indicators.
Jim Cramer: These 2 Stocks Are Soaring, and It Is All About the Democratic Race
UnitedHealth Group and JPMorgan are both bucking other trends to rise as more moderate leanings start to dominate the Democratic horse race.
UnitedHealth Group Is Poised for an Upside Breakout
Prices have rocketed higher since early October.
Jim Cramer: Here's Why the Market Hasn't Stopped Rallying
These are the 10 reasons why we keep going up, despite all the bad news.
Drug Companies Are a Political Football, Trading Amgen: Market Recon
The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.
Shorting the Dow at 27,000 May Not Be So Crazy
After seeing the idea raised -- and derided -- I found that the Dow has been over 27,000 twice this year and each time it did this....
Jim Cramer: Here's How You Get a Not as Bad as Feared Quarter
I have the answer behind the conundrum that forces stocks up that should be going lower.
Jim Cramer: Netflix and CSX Lead the 'NABAF' Earnings Story
These stocks's earnings were 'not as bad as feared,' and here are some more names that pushed the NABAF narrative.
Jim Cramer: The Market Is Lapping Up These Stocks
There are plenty of senior growth companies that can still move higher.
Markets Bet on Growth, 3 Month/10 Year Spread, Trading Nvidia: Market Recon
The Fed is doing this right. Let me repeat... the Fed is not screwing this up.
Key Market Observations
As mentioned earlier, breadth was only 2-1 positive with UnitedHealth , JPMorgan and Johnson & Johnson responsible for a large portion of the market's gains. Bond yields rose, aiding the rate-sensitive banks (who generally met expectations). FANG ha...
Advancers Over Decliners
"Only" about 2-1 advancers over decliners as UnitedHealth Care , JP Morgan and Johnson & Johnson account for a disproportionate amount of the market's rally.
Valuation and 2 Names to Watch Into Earnings: Market Recon
Citigroup and Lululemon are on the radar this morning.
